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There is no evidence that we are able to reverse
cerebral infarction once it gets underway. The day
may come when some form of protection for neuronal activity is available to us, but at present there is
no such treatment. Prevention is the most important
concept; prevention of transient ischemic attack
(TIA) or prevention of progression once the process
has started. Progressing stroke is that all too common
circumstance where focal ischemia is worsening and
the process of infarction is beginning or extending.
The patient may be seen in the office, emergency
room, or in the hospital, and the patient's classification may be changed on successive examinations.
There is nothing unusual about such reclassification.
For instance, a patient may be admitted to an intensive cardiac care unit with a tentative diagnosis of
myocardial infarction; the diagnosis will be changed
if the findings change. Thus we look at a patient
entering the hospital with a modest neurological defect in the right arm and reexamine the individual
some time later. If the defect is worse, we say that the
stroke is progressing; if the patient is the same, it
appears that the process is completed; if the defect
has disappeared, the diagnosis may be TIA.
It is important to differentiate between the carotid and vertebrobasilar systems. The neurological picture in progressing stroke in the carotid system may
range from monoparesis to hemiplegia with or without a homonymous defect in vision, a variety of
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impairments of speech and language, and a range of
partial to full sensory abnormalities on the opposite
side of the body.
The combination of defects in vertebrobasilar
occlusive events is often more complex. The most
common defects include abnormalities of motor
function; weakness, clumsiness, or paralysis of any
combination of the limbs with appropriate pyramidal
tract signs combined with unilateral or sometimes
bilateral cranial nerve palsies, particularly oculomotor defects or signs of trigeminal or facial nerve involvement. A so-called "crossed" defect (motor or
sensory on one side of the face and opposite side of
the body) is evidence of a brain stem lesion until
proven otherwise. Bilaterality of motor or sensory
abnormalities, or both, coupled with cranial nerve
palsies indicates brain stem involvement.
The work-up of a patient with acute progressing
stroke, whether in the carotid or vertebrobasilar arterial systems must proceed immediately. Particular
emphasis is placed on what we now call the neurovascular examination. Certain items have been
grouped together under this term. These include:
I. Inspection of vessels
2. Palpation of vessels
3. Auscultation at cervical and cranial sites
4. Ophthalmoscopy (including inspection of the
retinae for emboli, cotton-wool patches, vascular occlusions, hemorrhage, and ischemic
retinopathy)
5. Ophthalmodynamometry
l . Inspection of vessels. Cranial artent1s 1s an
unusual cause of stroke. However, accurate diagnosis
is vital to correct treatment, and significant arterial
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change may be detected by viewing the superficial
temporal arteries, coupled with palpation.
2 . Palpation of the cervical cerebral vessels
should be done gently. Minor differences in pulse
between sides are difficult to interpret and it may be
impossible to distinguish a pulse coming from the
first portion of the internal carotid artery or from the
ext(;,fnal carotid artery. Patients suspected of having
atherosclerosis of cervical vessels may have ulcerated
plaques or early thrombus formation ; both are situations where manipulation of the arteries could dislodge emboli .
3. Auscultation of the cervical vessels often provides important evidence of the pattern of blood
flow. A bell-type stethoscope is most easily applied in
the supraclavicular fossa and over the eyes, without
using physical pressure which may produce artifactual noise. The bell of the stethoscope is first
placed over the aortic valve and then moved ( 1 cm or
less at a time) upwards. This movement of the stethoscope is necessary to distinguish transmitted cardiac sounds from sounds arising in the innominate,
subclavian, common carotid, or internal carotid arteries. A neutral position (patient sitting or lying with
face straightforward) is less likely to create sounds
difficult to interpret than a variety of twisted neck
positions. If respiratory (tracheal) sounds obscure
auscultation, the patient is requested to "stop"
breathing for a few seconds and then instructed to
"start" breathing. Bruits should be graded for loudness, the scale being 1 (least) to 6 (loudest); for example 1/ 6 is barely audible, 6/ 6 is the loudest. The
timing (systolic, diastolic, systolic-diastolic), duration (short, medium, long), and quality (rough, soft,
smooth, and so forth) should be described. A bruit of
I / 6 loudness is of little significance, while one of 2/ 6
to 3/ 6 loudness, long systolic-diastolic duration, and
timing of fairly high pitch over the origin of the
internal carotid artery means high-grade carotid stenosis until proven otherwise. A soft (1 / 6 to 2/ 6)
diastolic sound, varying with slight change in neck
position, is usually an unimportant venous hum.
Soft, sometimes almost continuous, cervical bruits
are fairly common in children and ordinarily do not
indicate the presence of significant pathology. By
carefully recording the description of bruits and correlating this with arteriographical and other findings,
the examiner will quickly learn to interpret such
sounds correctly.
If the patient's history suggests the presence of a
neoplasm or arteriovenous malformation, ausculta-
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tion over the cranial vault and orbits should be performed. When there is a complaint of a rhythmic
head noise, particular attention is directed to auscultation of the site of the sound. It may be necessary to
wet the patient's hair to eliminate artifactual noise.
Auscultation of the orbit is performed by instructing
the patient to close the eyes, placing the bell of the
stethoscope over the eye, and having the patient open
the eyes to eliminate artifactual muse!F sounds. Soft
bruits over the cranial vault of chilr11. r~n
, ~1 are of little
importance. Loud bruits may be caused by angiomas,
an arteriovenous shunt, and, rarely, brain neoplasms.
A continuous, almost machinery-like murmur or
bruit over the orbit is most commonly caused by a
carotid cavernous arteriovenous shunt. Noises heard
over the orbit have been of little help in establishing
the site and severity of lesions of the internal carotid
artery.
4. Ophthalmoscopy provides an opportunity to
inspect small blood vessels directly; these blood vessels are a direct continuation of the internal carotid
arterial system. In office and hospital practice relatively little use is made of this simple, safe method of
acquiring important data concerning the cervicalcerebral portion of the circulation. The retina should
be inspected for arterial or venous occlusion, emboli
( cholesterol, platelet-fibrin, calcific, mixed, foreign
body), hemorrhages, cotton-wool patches, venous
stasis, microaneurysms, changes associated with arterial hypertension, papilledema, and ischemic retinopathy .
In the last two decades the importance of detecting a retinal embolus, or emboli, with the ophthalmoscope has been demonstrated. The most common
emboli are made up of cholesterol crystals. These
appear as shiny orange-yellow plaques often situated
at the bifurcation of retinal arterioles . The plaque
may appear to be wider than the arteriole; one sees
the outer dimension of the column of red blood cells
rather than the wall of the arteriole. Pressure on the
eye often changes the position of the embolus
slightly; the material may appear to glint or change
shade, a characteristic sometimes referred to as a
heliographic reflection. The blood flow in the arteriole often seems to be unimpeded by these bright
orange-yellow plaques. These emboli may move distally and often disappear in a few days. The presence
of one or more cholesterol retinal emboli indicates
that there is or has been an ulcerated atheromatous
carotid (internal) lesion until proven otherwise.
Another important type of embolus in retinal
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vessels consists of gray-white material, thought to
consist of blood platelets and fibrin. These emboli
may be long and seen to move through an arteriole
but are commonly stationary; pressing on the eye
does not move the embolus, and there is no heliographic reflection. Blood does not appear to flow past
these emboli; there may be infarction of the retina.
Special studies show that some of these emboli have a
high lipid content. In many instances the source of
these emboli is an atheromatous lesion at the origin
of the internal carotid artery . Particles of calcium
form another type of retinal embolus. These are
white, generally short, and stationary. Calcium emboli commonly come from heart valve lesions.
Septic emboli, talc, cornstarch, and other less
common emboli may also be seen in the retina .
5. Ophthalmodynamometry is a procedure for
measuring arterial systolic and diastolic pressures in
the main retinal branch or branches of the ophthalmic artery. The convex foot-plate of the instrument is
applied to the conjunctiva over the insertion of the
lateral rectus muscle in a horizontal manner so that
the instrunient points directly toward the opposite
eye. When measurements are being made in the
patient's right eye, the instrument is held in the observer's left hand and the ophthalmoscope is held in
the right hand . To measure pressure in the left retinal
artery, the observer holds the ophthalmodynamometer in the right hand and the ophthalmoscope in the
left. When the instrument is in position, the observer
must bring the central artery on the disc into focus
through the ophthalmoscope. The instrument is then
pressed gradually against the eye to raise the intraocular pressure sufficiently to exceed the diastolic
level of the blood pressure in the retinal artery. The
diastolic pressure is that level which produces the first
collapsing pulsation of the artery. At this point, a
finger is applied to the brake on the instrument a nd
the reading is taken from the scale. The ophthalmodynamometer is reapplied and several more readings are taken to insure accuracy . The systolic pressure is obtained by increasing the force of application
of the instrument still further. The visible arterial
pulsation gradually diminishes as the pressure increases and when pulsation ceases, the reading on the
instrument is the systolic blood pressure. Ophthalmodynamometry is usually useless unless the arterial
press ures are measured in both eyes. It cannot be
performed unless the patient is cooperative. It is helpful to instill a mydriatic, but this should not be done
if there is glaucoma. The test should not be per-

formed soon after cataract extraction or recent retinal detachment. The clinical significance of the retinal arterial pressure is dependent on comparing the
values in the two eyes. A difference of 15% to 20% is
almost a lways a sign of stenosis or occlusion of the
internal carotid artery ipsilateral to the lower pressure. The arterial pressures may be equal or normal
or both in the presence of unilateral carotid stenosis
or occlusion because of the development of a collateral blood supply. Immediately following acute occlusion of an internal carotid artery, the ipsilateral
retinal artery pressure drops . Return of the pressure
to that of the contralateral eye depends on the speed
with which the collateral circulation develops. A
marked decrease in retinal arterial pressure (brachia!
arterial pressure remaining normal) when the patient
moves from the supine position to the upright position (ocular orthostatism) is important evidence of
carotid occlusive disease.
A number of laboratory tests should be performed. These include common items such as urinalysis, red blood count, white blood count, differential blood count, blood hemoglobin, sedimentation
rate, fasting blood sugar, creatinine or urea, prothrombin time, cholesterol, triglycerides, and uric
acid. It is important to make a diagnosis of such
items as polycythemia; it has been known for decades
that there is a high incidence of focal cerebrovascular
disease in individuals who have this disorder. One
may do a platelet count although it is extraordinarily
unusual for thrombocythemia to be a cause of progressing stoke. When cranial arteritis is present, the
sedimentation rate will be elevated; this diagnosis
should be made quickly because of the risk of permanent impairment of vision. Diabetes is a part of
the risk factor profile for stroke and the fasting blood
sugar will assist in detecting individuals with this disorder. Renal function should be screened and the prothrombin time determined for baseline value. In
acute progressing stroke, cholesterol and triglycerides
are proba bly not of much significance unless they are
excessively raised . The uric acid has been determined
mainly as an item for study beca use of the association of hyperuricem ia with atherosclerosis; the value
is often elevated in patients with stroke.
It is common to do x-rays of the head although
the number of instances where a significant abnormality is detected is small. X-rays of the chest are
done and an electrocardiogram is performed. The
possibility of a hidden myocardial infarction is always present; other evidence of cardiac abnormality
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may also be of importance in the long-range management of the dis9 rder.
Cerebrospinal fluid examination should be performed (when choke is absent due to papilledem a)
when the clinician has a serious problem in establishing the differential diagnosis of the intracranial pathology-bleeding, focal ischemia or inflammatory
disease . The common problem for differenti a l di agnosis in this setting is bleeding; only a small amou nt
of fluid needs to be withdrawn to settle this question .
In the usual stroke patient (in a typical TIA, in
most instances of progressing stroke, and in amost all
cases of completed stroke) the electroencephalogram
adds little significant information and is not necessary in the work-up of the patient. Commonly, in
vertebrobasilar disease, the electroencephalogram
shows no focal abnormality. It has been said that
serial electroencephalograms may very well portray
accurately the favorable or unfavorable progression
of the brain lesion in stroke. However, the clinician
can almost always get this information by spending
three or four minutes with the patient one or more
times a day. In selected instances, an electroencephalogram may reveal multiple focal abnormalities, thus
giving potential evidence concerning the presence of
multiple metastatic lesions. Particularly in . medical
centers where computerized axial tomography (EM!
scanner, ACT A scanner, DELTA scanner, and others) is available, there is very little need for the electroencephalogram in the diagnosis of stroke patients .
Doppler techniques, including the use of a Doppler
flowmeter are under research and may be developed
for clinical use . The static isotope brain scan has
become an established procedure for the detection of
intracranial neoplasms . However , where computerized axial tomography is available, there is now
very little need for the static brain scan in the differential diagnosis of focal brain lesions . Likewise, dynamic rapid serial sciptigraphy using a gamma camera, which gives a serial display to the images,
provides much less precise information of clinical
significance than computerized axial tomography or
arteriography.
Indications for angiography are:
I. Differential diagnosis of the brain pathology
(much less often used in institutions where computerized axial tomography is available).
2. Transient focal ischemic attacks-particularly the carotid system. In such instances , cervicalcerebral angiography should be performed if there
is one, or more than one, of: amaurosis fugax , bruit
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over the beginning of the internal carotid artery, retina l emboli, unilateral decrease in retinal artery pressure, or ischemic retinopathy.
3. Selected instances of vertebrobasilar T!As. In
some instances, it may be difficult to make a clinical
distinction between the carotid and the vertebrobasilar system. If the T!As are characteristic of those
coming from the vertebrobasilar system, there is little
reason to do extensive angiography.
4. Very early progressing stroke or very frequent
T!As in the carotid system with, as part of the history, amaurosis, an appropriate bruit, retinal emboli,
and so forth.
5. Many patients with subarachnoid hemorrhage and some patients with intracerebral hemorrh age.
6. A long systolic or systolic-diastolic carotid
bruit, particularly with retinal emboli.
This completes the work-up of the patient.
As the patient with acute progressing stoke is
worked up, the physician is interested in prognosis.
Little has been written about this , if one starts with
patients early in the course of their illness. It is importan t to understand that mortality statistics will vary,
depending upon the type of hospital, nature of the
population being hospitalized, avai lability of intensive care units, and other factors. Recently Jones
and Millikan 1 studied the records of 179 consecutive
patients with acute carotid system cerebral infarction
to describe the clinical events during the first week
of the illness. Only those patients ad mitted to the
Cerebrovascular Hospital Service within 36 hours of
the onset of the first symptom were included. The
neurologica l status of 39% was stable (unchanged) at
the end of seven days; 35% of the patients gradually
improved. Nineteen percent had a progressing neurological deficit which stabilized within 48 hours of theonset. Six patients (3 %) had a remitting-relapsing
course during the first 36 hours and eight patients
(4%) had a significant late worsening after 48 hours
of stable or improving course. The mortality was 11 %
for the entire group . However, a "high risk of death"
group was identified; the mortality was 41 % for those
patients who had any degree of decreased level of
consciousness and hemiplegia at the time of admission. Of 67 patients having hemiplegia or some similar maximum neurologica l deficit with normal consciousness when admitted, only one died , a mortality
of less than 2%. These percentage values have become
a baseline for us to use in our institution in comparing possible new therapy with the results of earlier
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treatment. In a hospital where there is a sizable population of patients with acute onset cerebral infarction,
it probably would be wise to determine similar percentages; the data could then also be used as a baseline for that particular hospital.
_Therapy. The primary objective of therapy in
occlusive cerebrovascular disease is to maintain a
normal or adequate metabolic substrate by maintaining the quality and quantity of blood delivered and
removed from brain tissue. This primary goal may
need to be attained by treatment of any mechanism
which:
I. Interferes with the cardiac capacity to maintain adequate cerebral perfusion,
2. Alters any property of the blood which may
maintain adequate neurometabolic substrate (including thrombus formation, anemia, and so forth),
3. Changes in the arterial wall leading to occlusion or thrombus formation (including atherosclerosis,
arteritis, and so forth),
4. Affords transient protection of certain aspects
of neuron metabolism (hypothermia, steroids, and so
forth).
Treatment will be discussed under the following
categories: I) therapy related to the heart, 2) therapy
related to alterations of the blood, 3) management of
problems concerning the arterial wall, and 4) treatment concerning protection of brain parenchyma.
I. Heart. When there is any kind of causal relationship between cerebral infarction and a change in
cardiac rhythm the cardiac dysrhythmia should be
corrected. If there is impaired cardiac output,
whether due to primary cardiac failure or to hypertension from some systemic abnormality, the cardiac
output should be returned to normal. There is uncertainty about the percentage of occlusive disease
strokes caused by embolism (mainly from the heart);
it may well be higher than previously suspected. Cerebral embolism may occur at various times after myocardial infarction with mural thrombosis, but it most
commonly comes within the first six weeks after the
infarction. Anticoagulant therapy has been recommended. The principal reason for using an anticoagulant is to prevent the release of further emboli to the
brain and other sites. The use of an anticoagulant
continues to be a common recommendation in instances where prosthetic cardiac valves have been
implanted. When the cause of cerebral infarction is
related to subacute bacterial endocarditis, it continues to appear to be unwise to use anticoagulants.
Rather rarely, progressing stroke is a portion of

the substructure of hypertensive encephalopathy. The
use of the term "hypertensive encephalopathy" is
specifically reserved for a syndrome in which there is
a stereotyped sequence of events of serious import
and dramatic development; in such instances, treatment consists of immediate control of the hypertension. In the usual progressing cerebral infarction,
hypertension should be treated cautiously-the blood
pressure not being decreased precipitously. If an anticoagulant is being used, the blood pressure should be
brought under control, but this need not be done as
emergency therapy.
2. Blood constituents. There are very few reports
in the literature in which the term "progressing
stroke" is used in relatively uniform fashion and
comparison made between a group of patients treated
with anticoagulant and a group not receiving such
medication. The extraordinary variability in the natural history of acute progressing stroke makes it important that comparison be made of treated and untreated patients of similar type. Over two decades
ago, I reported on the natural history of 204 consecutive patients with acute onset of progressing
stroke in the carotid system. Fourteen days after the
onset, 12% of the patients were normal, 5% (using
motor phenomena as a basis for comparisons) had
varying degrees of monoparesis, 69% had varying
degrees of hemiparesis, and 14% were dead.
The Table summarizes those studies reported in
the literature which are relatively comparable. A
primary determination was made of the status of the
patient at the time of the patient's admission to the
study; progression of the neurological deficit had occurred in the preceding few minutes. There was frequent reevaluation of the neurological deficit, and
subsequently compaHson was made between the
maximal deficit developed and the deficit present on
entering the study. The percentage of patients showing progression of neurological deficit (after primary
assessment) in the control and treated groups of each
report is in die right-hand column of the Table. In
every instance, the treated group fared better than
those not receiving an anticoagulant; thus, in one
study ,2 20% of those treated showed evidence of neurological progression after entry into the study,
whereas 52% of patients not receiving an anticoagulant showed progression after initial evaluation.
Thus, in a few carefully performed investigations using an anticoagulant for acute progressing stroke, the
evidence points to fewer patients having progression
when receiving an anticoagulant contrasted to the
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Study
Millikan'
Control
Treated
Carter'
Control
Treated
Cooperative Study'
Control
Treated
Fisher'
Control
Treated
Fisher (National Study )'
Contro l
Treated

Number
of
Patients

Followup
(Mos.)

Cerebral
In farcts
(Lethal)

Cerebral
Hemorrhage
(Leth a l)

Progressive
Infarcts

Total
Percentage
Progressive

60
181

12
12

25 (40%)
12(7% )

0
0

8 (13% )
25(14% )

52%
20%

38
38

6
6

7 (1 7%)
3 (7% )

0
0

12 (33% )
9(24% )

50%
32%

67
61

15
12

10 (15%)
5(8%)

0
I (2% )

2 1 (31 % )
8(1 3% )

46%
23%

14
14
49
51

0
0
7.4
5.7

number having progression and not getting such
drugs.
If one considers the use of platelet antiagglutinating agents, there are no current data concerning
the effectiveness of such drugs as dipyridamole, aspirin, or sulfinpyrazone in the treatment of acute progressing stroke. Gilroy et aF reported the treatment
of acute stroke with low molecular weight dextran
and were optimistic about the effect of the medication. Apparently, however, no widespread enthusiasm for this method of treatment has developed .
The notion that a fibrinolytic (thrombolytic)
agent could lyse a clot obstructing arterial flow to the
brain has always been an attractive one. Fletcher et
al 8 have recently reported a study of the use of the
thrombolytic agent, urokinase, in doses sufficient to
produce a twenty- to fortyfold increase of plasma
thrombolytic activity . However, hemorrhagic complications occurred in several patients and distinctly
favorable therapeutic results were not observed.
No comparative studies have been done to guide
treatment of polycythemia, anemia, and hypoglycemia in acute progressing stroke. It is presumed that
as soon as feasible these phenomena should be corrected and normal values attained. In a usual acute
progressing stroke, hyperlipidemia does not receive
special therapeutic attention during the first days of
hospital a dmission .
If hyponatremia, hypernatruria, and increased
urine osmolality are present [evidence of inappropriate antidiurectic hormone (ADH) secretion], fluid intake should be restricted to approxi-

7
4

0
0

9
3
14(29%)
7( 14% )

64%
21 %
20(40% )
7 (14% )

mately 1000 cc/ day until the abnormality has
disappeared.
3. Arterial wall. The idea of improving the status
of a progressing cerebral infarct by some treatment
causing vasodilatation took a practical form in 1938
when Mackey and Scott0 described the treatment of
apoplexy by infiltration of the stellate gangli on with
novocaine and reported that marked benefit was produced. A variety of techniques for causing vasodilatation have been invoked including the inhalation of
5% carbon dioxide, and the administration of papaverine, isoxsuprine and acetazolamide. In summary,
no general enthusiasm has developed for this type of
treatment of progressing cerebral infarction.
The use of hypocarbia has also been studied by
Paulson. 10 No therapeutic benefit was found, so there
is no reason to pursue this method of therapy.
When cerebral infarction occurs secondary to
arterial obstruction associated with any form of arteritis or meningitis, attention must be paid to treatment of the primary disease causing the lesion of the
arterial wall. Panarteritis, lupus erythematosis, cranial arteritis, and so forth, ordinarily receive steroid
therapy while meningitis is treated with antibiotic or
other agents, depending upon the organism producing the inflammation.
There is a differ.e nce of opinion concerning emergency surgery for patients with rapidly changing flow
in the cervical portion of the carotid artery. Blaisdel111 believes that individuals with progressing stroke
should probably not have arteriographic evaluation
because of the high risk of surgery or the small possi-
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bility of a favorable result. The Joint Study of Extracranial Arterial Occlusion 12 reported a mortality of
42% in 50 patients operated upon within two weeks
following an acute stroke while the mortality was
only 20% for patients in the same category not having
surgery. Bruetman et .a1' 3 and Wylie et a1 14 have reported intracerebral hemorrhage as a complication of
carotid surgery. Apparently, the opening of carotid
occlusion, reestablishing a normal head of perfusion
pressure into an area of acute softening, may be
associated with the production of intracerebral bleeding. In contrast, Millikan 15 has reported a group of
carefully selected individuals, in whom emergency
anticoagulant therapy and surgery appeared to be
beneficial. The indications for emergency treatment
are: 1) clinical events such as a cluster of frequent
severe carotid TIAs (a persisting mild neurological
deficit accumulates as evidence of mild progressing
stroke); 2) a recent mild cerebral infarction in the
carotid system followed by a cluster of TI As; 3) onset
of a focal neurological deficit during or soon after
arteriography; or 4) sometimes immediate postoperative thrombosis after carotid thromboendarterectomy,
and physical signs such as a) retinal emboli, b) long
systolic or systolic-diastolic bruit of grade 2 or 3 over
the carotid bifurcation, or c) ipsilateral decrease in
the retinal artery pressure. A changing carotid bruit
suggesting a change in the morphology of the carotid
lesion probably should be added to this list of physical signs-signs which coupled with the clinical profile
suggest that emergency surgery should be instituted.
4. Protection of brain parenchyma-anti-edema.
A. Steroids. Dyken and White16 found the incidence of death in patients with acute cerebral infarction to be the same whether they were treated
with cortisone (300 mg/day) or a placebo. Rubinstein'7 noted that the immediate mortality may be
reduced and the level of consciousness may be improved when large doses of dexamethasone are administered early in the course of massive cerebral
infarction, but once the slightest degree of brain stem
dysfunction has occurred, the use of steroids appears
to be without benefit. Patten et al 18 reported some
slight benefit from the use of dexamethasone in acute
stroke in a double-blind study, but if cases of cerebral
hemorrhage were excluded, the results were unconvincing. Bauer and Tellez 19 found no difference in
morbidity or mortality in 54 patients with acute cerebral infarcts divided into steroid-treated and placebo
groups. In a recent report, Norris 20 studied 53
patients with acute cerebral infarction using a

double-blind method. One group was treated with
dexamethasone and the other portion with placebo,
and all observations began within 24 hours of onset
of the cerebral infarction. Forty-one of the total number of patients survived longer than 28 days; the
patients treated with steroid did slightly worse than
those in the placebo group at the end of this time.
Two of five individuals who died in the placebo group
died of cerebral edema; compared with three of seven
patients who died in the steroid group. Because of
problems with infectious complications, gastrointestinal hemorrhage, and an occasional serious worsening of diabetes mellitus in the steroid group, Norris
believed that there was an increasing body of evidence against the use of such medication in the treatment of acute cerebral infarction.
8. Hyperosmolar therapy. In certain instances,
intravenous administration of hypertonic agents may
reduce the fluid content of the brain. Mannitol , in
concentrations of 10% to 25%, may be administered
intravenously in a dose of I gm/ kg of body weight.
When it is effective, the maximal reduction of intracranial pressure is achieved within 30 to 60 minutes. However, intracranial pressure often returns
quickly to normal. At least, from the lack of reports
in the literature, this substance is not widely used in
the treatment of acute progressing cerebral infarction.
Meyer et al 21 reported treatment of cerebral edema due to acute cerebral infarction with glycerol.
The glycerol was given intravenously in doses of 1.2
gm/ kg of body weight or, in other instances, orally in
doses of 1.5 gm/ kg of body weight. The authors
believe that glycerol " given within five days of onset
of severe, progressing or sustained neurological deficit, is beneficial in patients with acute cerebral infarction." Gilsanz et al2 2 compared treatment with
10% glycerol given for six days to 30 patients with
acute cerebral infarction to results obtained after
treating 31 similar patients with dexamethasone. One
patient treated with glycerol died of hemoglobinuria
and acute renal failure while six patients treated with
dexamethasone died. The authors concluded that improvement was significantly greater in the glycerol
group after 8 and 15 days. The results of these observations appear to require further study.
Although hypothermia, anesthesia, hyperbaric
oxygen ation and normobaric oxygenation might theoretically provide a favorable metabolic substrate for
focal areas of brain ischemia, none of these are therapeutically practical for progressing stroke.
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When convulsions, either at the time of progressing stroke or subsequently, become a problem, it is
prudent to administer an anticonvulsant. The drug
most commonly used is diphenylhydantoin, now
called phenytoin (Dilantin®).
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